Prestige Consumer Healthcare

Prestige Consumer Healthcare is a holding company. Through its subsidiaries, the company develops, manufactures, markets, sells and distributes over-the-counter (OTC) healthcare products to mass merchandisers and drug, food, dollar, convenience, and club stores in North America (the U.S. and Canada) and in Australia and certain other international markets. The company's portfolio of OTC Healthcare products includes, among others, DenTek oral care products, Monistat women's health products, Nix lice treatment products, Chloraseptic sore throat treatments, Clear Eyes eye care products, Compound W wart treatments, Luden's throat drops, BC and Goody's pain relievers and Debrox earwax remover.
  • TickerPBH
  • ISINUS74112D1019
  • ExchangeNew York Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Reason For Caution Various market dynamics have deteriorated recently which leads us to a more neutral outlook for the weeks ahead. For now we do not expect to see a significant correction, however we have reason to believe that this current consolidation period could go on longer than initially expected. Below we explain updates to our outlook. · Deteriorating Market Dynamics: US Dollar & EM Equities. The 92 level has been our key line in the sand on the US dollar (DXY); we have suggested that if the DXY is above 92 we see it as a risk-off signal for global equities -- and here it ...

PRESTIGE CONSUMER reduced its risk exposure resulting in an upgrade to Slightly Positive

PRESTIGE CONSUMER (US), a company active in the Drug Retailers industry, reduced its market risk and raised its general evaluation. The independent financial analyst theScreener awarded an improved star rating to the company, which now shows 3 out of 4 possible stars; its market behaviour has improved and can be considered as defensive. theScreener believes that this new assessment merits an overall rating upgrade to Slightly Positive. As of the analysis date March 16, 2021, the closing price was USD 46.88 and its potential was estimated at USD 49.22.

Prestige Consumer Healthcare Inc: 1 director sold after exercising options/sold

A director at Prestige Consumer Healthcare Inc sold after exercising options/sold 12,264 shares at 42.637USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is rest...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • A number of names in the Communications Sector are showing signs of leadership. (ex. GLUU, TWTR, GOOGL, NYT, and NWSA) • Consumer Discretionary continues to have a number of attractive names technically. (ex. TPR, LGIH, DHI, VSTO, RGR, PENN, SGMS, BYD, BJRI, BKE, EBAY, SIG, HAIN, and ENR ) • A number of Financial Sector names appear to be perking up. (ex. JHG, INTL, EVR, GHL, ARR, and CINF)

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: Many health care names are staging reversals and breaking above bullish bases, including IVC, CUTR, VREX, EHC, SEM, AMED, MD, HAE, RGEN, BIO, LCI, PBH, Semiconductor and semi-suppliers continue to be leadership (ex. ACLS, VECO, COHU, QRVO, SWKS, SYNA, CRUS, SMTC, QCOM) A number of auto component suppliers appear to be bottoming (ex. AXL, DAN, BWA)

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

• A number of Healthcare names are pulling back to logical support areas. (ex. EW, EGRX, ARWR, RGEN, LCI, CTLT, and PBH) • The Technology Sector continues to have a number of technically attractive names that are pulling back to support levels. (ex. FORM, MKSI, NVDA, MU, SYNA, ANSS, COHR, and WDC) • Defensive Sectors such REITs and Consumer Staples remain leadership. (ex. LW, PEP, UHT, NSA, COR, and LSI)

Prestige Consumer Healthcare Inc: 1 director sold after exercising options/sold

A director at Prestige Consumer Healthcare Inc sold after exercising options/sold 12,264 shares at 42.637USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is rest...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Reason For Caution Various market dynamics have deteriorated recently which leads us to a more neutral outlook for the weeks ahead. For now we do not expect to see a significant correction, however we have reason to believe that this current consolidation period could go on longer than initially expected. Below we explain updates to our outlook. · Deteriorating Market Dynamics: US Dollar & EM Equities. The 92 level has been our key line in the sand on the US dollar (DXY); we have suggested that if the DXY is above 92 we see it as a risk-off signal for global equities -- and here it ...

MarketLine Department

Maple Leaf Foods Inc. - Strategy, SWOT and Corporate Finance Report

Summary Maple Leaf Foods Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Maple Leaf Foods Inc. (Maple Leaf or 'the company') is a consumer protein company that produces prepared meats and poultry products. The company offers a range of products, such as prepared meats, pork, ready-to-cook and ready-to-serve meals, poultry, turkey, and plant protein products...

MarketLine Department

Orkla ASA - Mergers & Acquisitions (M&A), Partnerships & Alliances And Investments

Summary Marketline's Orkla ASA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Orkla ASA since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highlights Th...

MarketLine Department

Chattem Inc - Strategy, SWOT and Corporate Finance Report

Summary Chattem Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Chattem Inc (Chattem), a subsidiary of Sanofi SA, is a consumer healthcare company based in the US. The company manufactures, markets and distributes branded consumer healthcare products, toiletries, proprietary drugs, fragrances and dietary supplements. It offers skin and hair care products suc...

MarketLine Department

Orkla ASA - Strategy, SWOT and Corporate Finance Report

Summary Orkla ASA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Orkla ASA (Orkla) is a supplier of branded consumer goods and concept solutions to grocery, specialist retailers, bakery, and out-of-home markets. The company’s products portfolio include margarine and butter blends, marzipan and ice cream, bread and cake improvers and mixes; house hold care and p...

Prestige Brands, Inc.: Loan Covenant Quality Snapshot

CORPORATES ISSUER IN-DEPTH 21 July 2017 Facility Size; Maturity: Term B-4: $1,427m; 26 Jan 2024 (but springing maturity to 91 days before the 2021 Notes maturity date or 2024 Notes maturity if either has > $100m of debt outstanding) Incremental: $350m plus amount so consolidated first lien net leverage ratio ≤ 4.0x Pricing: Term B: Eurocurrency rate + 2.75% / ABR + 1.75% initiall

PRESTIGE CONSUMER reduced its risk exposure resulting in an upgrade to Slightly Positive

PRESTIGE CONSUMER (US), a company active in the Drug Retailers industry, reduced its market risk and raised its general evaluation. The independent financial analyst theScreener awarded an improved star rating to the company, which now shows 3 out of 4 possible stars; its market behaviour has improved and can be considered as defensive. theScreener believes that this new assessment merits an overall rating upgrade to Slightly Positive. As of the analysis date March 16, 2021, the closing price was USD 46.88 and its potential was estimated at USD 49.22.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch